Equipped with state-of-the-art facilities and experienced Immuno-oncology experts, Creative Biolabs specializes in engineering cancer cells by the adeno-associated virus for our global clients.
Adeno-associated virus (AAV) is one of the most actively studied gene therapy vectors. It was first discovered as a contaminant of adenovirus preparations. Simply put, AAV is a protein shell surrounding and protecting a small, single-stranded DNA genome of approximately 4.8 kilobases (kb). AAV belongs to the parvovirus family and relies on co-infection with other viruses, mainly adenoviruses, for replication. Molecular cloning of AAV genes was initially isolated serologically, and hundreds of unique strains of AAV have been identified in many species. AAV contains a small single-stranded DNA genome of about 4.8 kilobytes (kb) which covers three genes: Rep (Replication), Cap (Capsid), and aap (Assembly). These three genes produce nine gene products at least by using three promoters, alternative translation start sites, and differential splicing. These coding sequences are flanked by inverted terminal repeats (ITRs), which are necessary for genome replication and packaging.
Fig.1 Diagram of rAAv transduction pathway. (Wang, et al., 2019)
Recombinant adeno-associated virus (rAAV) vectors have been used as gene therapy vectors. As there are many considerations for any viral vector. Which contain being able to attach to and enter the target cells, successfully transfer to the nucleus, being able to sustain expression in the nucleus for a period of time, and lack toxicity. AAV vectors meet all of these criteria perfectly. At the same time, various modifications have enhanced their utility.
Currently, rAAV vectors for gene therapy are mainly based on AAV-2. The AAV-2-based rAAV vectors can transduce muscle, liver, lungs, brain, and retina, and takes several weeks to achieve optimal expression. AAV vectors seem to be a promising gene delivery vehicle based on their safety and therapeutic efficacy. Two AAV-based drugs (Luxturna and Zolgensma) have been approved by the FDA, and clinical trials using AAV-based therapies in patients with genetic and non-genetic disorders are ongoing.
Based on a thorough study of AAV-based vectors, Creative Biolabs specializes in engineering cancer cells by the adeno-associated virus to help our clients shorten their research journey. We are committed to engineering cancer cells via genetic methods and are dedicated to reducing the overall project development timeline for our clients.
Our provided synthetic gene circuits for cancer immunotherapy-related services include the following, but are not limited to:
For further details, please don't hesitate to contact us.
Reference
For Research Use Only | Not For Clinical Use
Download our brochure